Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
VE Kennedy, CC Smith - Frontiers in Oncology, 2020 - frontiersin.org
The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
P Montesinos, C Recher, S Vives… - … England Journal of …, 2022 - Mass Medical Soc
Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …
NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines
DA Pollyea, D Bixby, A Perl, VR Bhatt… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the
diagnosis and treatment of adults with AML based on clinical trials that have led to …
diagnosis and treatment of adults with AML based on clinical trials that have led to …
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase …
CD DiNardo, AC Schuh, EM Stein… - The Lancet …, 2021 - thelancet.com
Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Conventional therapy for acute myeloid leukemia is composed of remission induction with
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
T Herold, M Rothenberg-Thurley, VV Grunwald… - Leukemia, 2020 - nature.com
Abstract The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for
diagnostic subtyping, prognosis, and patient management. However, cytogenetic …
diagnostic subtyping, prognosis, and patient management. However, cytogenetic …
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
N Daver, S Venugopal, F Ravandi - Blood cancer journal, 2021 - nature.com
Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
C Rausch, M Rothenberg-Thurley, A Dufour… - Leukemia, 2023 - nature.com
Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …